Wednesday, June 24, 2026
← Back to archivePolicy
Policy•STAT News•Jun 24, 2026
Opinion: New human embryo editing advances require tough conversations on ethical boundaries
background ▾
- •Base editing shows promise for safer human embryo editing with less off-target damage, but remains unsafe for clinical use and lacks medical justification over existing embryo screening methods for genetic disease prevention.
- •The ethical debate extends beyond disease prevention to enhancement applications; the author advocates for a temporary moratorium on heritable editing while international ethical frameworks are developed, not a complete research ban.
- •Watch for: international consensus-building on human embryo editing guidelines, regulatory responses from major jurisdictions (US, EU, China), and peer-reviewed publication of Egli's preprint findings.
Policy•KFF•Jun 23, 2026
U.S. Global Health Legislation Tracker
background ▾
- •Over 50 global health bills are pending in the current Congress, with some introducing companion bills across chambers
Policy•KFF•Jun 23, 2026
The Medical Frailty Exemption from Medicaid Work Requirements: Key Takeaways from the CMS Interim Final Rule
background ▾
- •CMS's restrictive medical frailty definition requires proof that conditions impair ability to engage in community activities (work/volunteer), not just categorical diagnosis—a functional test that differs from early state expectations
- •States must develop auditable lists of qualifying conditions and face financial penalties if determinations lack adequate clinical support, creating significant compliance risk and operational complexity before the January 1, 2027 deadline
- •Implementation challenges may widen coverage gaps and create enrollment barriers for medically frail populations; monitor state compliance outcomes and litigation over exemption denials beginning in 2027
Policy•Endpoints News•Jun 23, 2026
BIO board met with US officials on China, CEO says
background ▾
- •BIO is actively engaging U.S. government officials on China biotech competition strategy, signaling the industry's view that political and trade policy coordination is necessary
- •Companies are grappling with how to compete with or regulate China's biotech sector, indicating this has become a material business consideration for the sector
Biotechnology Industry Organization
→ Read original articlePolicy•Endpoints News•Jun 23, 2026
Trump backs psychedelics, but CDMOs hold back for now
background ▾
- •Trump's executive order on psychedelics represents a significant policy pivot that could reduce regulatory friction for psychedelic drug development
- •CDMOs are not increasing psychedelics manufacturing capacity in response, indicating that supply-side infrastructure remains a bottleneck despite policy support
- •Watch whether CDMOs shift strategy following clarification of the executive order's scope and funding mechanisms, and monitor FDA guidance on psychedelics manufacturing standards
Market Access
Market Access•Fierce Biotech•Jun 23, 2026
Serapha Bio takes flight from Boundless merger with $230M and gene-editing prospect from China
background ▾
- •Serapha Bio launches with $230M funding to advance SERP-01 base editing therapy for AATD, a 40-year treatment gap with 100,000 severe U.S. patients lacking approved disease-modifying options
- •YolTech retains China rights and $2B+ in milestones, while Boundless Bio provides public-market infrastructure via reverse merger, de-risking regulatory and operational execution
- •Direct competition intensifying: Sanofi's phase 2 data for recombinant protein efdoralprin alfa and Wave's WVE-006 RNA editor both recently showed efficacy, compressing market opportunity window for Serapha's entry
Serapha BioBoundless BioYolTech TherapeuticsSERP-01BBI-940efdoralprin alfa
→ Read original articleMarket Access•Fierce Biotech•Jun 23, 2026
Merck KGaA pledges $50M to build new cardio biotech with eye to later acquisition
background ▾
- •Merck KGaA has secured exclusive acquisition rights to a genetic cardiomyopathy biotech, directly addressing management's publicly stated weakness in early-stage pipeline strength.
- •The $50M investment plus milestone-based payments and minority stake structure represents a lower-risk incubation model compared to outright acquisition, with option to consolidate upon clinical validation.
- •Watch for preclinical milestone readouts that trigger additional Merck KGaA funding and progress toward IND-enabling studies in single-gene cardiomyopathies.
Merck KGaAVersant VenturesSaturnus Bio
→ Read original articleMarket Access•Fierce Biotech•Jun 23, 2026
Big obesity bets and China's rise fuel potential $2T in 2032 drug sales: Evaluate
background ▾
- •Tirzepatide is projected to become the highest-grossing drug ever at $70B+ in 2032 sales, surpassing Humira, Keytruda, and COVID vaccines combined
- •Eli Lilly is forecast to dominate the obesity/metabolic space with nearly 50% of top-10 drug sales, including Mounjaro, Zepbound, Foundayo, and pipeline assets retatrutide and eloralintide
- •Novo Nordisk's semaglutide franchise (Ozempic/Wegovy) expected to slip outside top-10 best-sellers due to inferior efficacy vs. dual-mechanism competitors, despite $25B+ collective sales potential
Eli LillyNovo NordiskAbbVietirzepatideMounjaroZepbound
→ Read original articleMarket Access•Fierce Biotech•Jun 23, 2026
Sangamo to put ‘substantially all’ assets for sale in bankruptcy, lines up Lilly and Astellas as buyers
background ▾
- •Sangamo's bankruptcy represents a significant consolidation event in the gene therapy sector, with two major pharmas acquiring multiple validated platform technologies and clinical-stage programs at distressed valuations
- •Astellas's acquisition of isaralgagene civaparvovec—which had phase 1/2 data supporting accelerated approval potential—marks a strategic entry into Fabry disease gene therapy despite the biotech's failure to advance it independently
- •Monitor whether other Sangamo assets (ST-503, giroctocogene fitelparvovec, Treg program) find buyers in the broader auction process, and track regulatory timelines for programs in transition during bankruptcy administration
Sangamo TherapeuticsEli LillyAstellas PharmaST-506isaralgagene civaparvovecST-503
→ Read original articleMarket Access•Endpoints News•Jun 23, 2026
Osanni Bio gets $190M to build ophthalmology and cardiology pipeline
background ▾
- •Osanni Bio raises $190M to build out ophthalmology and cardiology pipelines through affiliate company structure
Osanni Bio
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Jun 23, 2026
Pfizer’s first new ADC from Seagen acquisition fails phase 3 NSCLC trial
background ▾
- •Sigvotatug vedotin failed to meet OS primary endpoint versus docetaxel in SigVie-002, marking a significant setback for Pfizer's most-advanced post-Seagen ADC asset.
- •Exploratory subgroup analysis in one-prior-therapy patients shows a 'stronger trend' in OS and PFS, justifying continuation of the combination strategy with pembrolizumab in first-line NSCLC (phase 3 Be6A Lung-02).
- •Watch the Be6A Lung-02 combination trial readout; monitor Pfizer's portfolio rationalization and whether next-generation IB6 candidate (with Topo1 payload) or PD-L1 ADC fetrastobart vedotin can validate the ADC platform post-acquisition.
PfizerSeagenMerck & Co.sigvotatug vedotindocetaxelpembrolizumab
→ Read original articleClinical Trials•Endpoints News•Jun 23, 2026
Boundless Bio reverse merger; CARsgen wins first solid tumor approval for CAR-T
background ▾
- •CARsgen's solid tumor CAR-T approval is a landmark achievement that validates the broader CAR-T platform beyond blood cancers and could reshape the competitive landscape for cell therapies
- •The article mentions multiple companies (Definium, uniQure, MoonLake, Corxel, US WorldMeds) but provides insufficient detail to assess their significance
- •Watch for CARsgen's clinical data presentation, commercial strategy, and whether other CAR-T developers can replicate this solid tumor success
CARsgen TherapeuticsBoundless BioDefinium TherapeuticsCAR-T cell therapy
→ Read original articleClinical Trials•Fierce Biotech•Jun 23, 2026
Corxel gears up for global pivotal push after oral GLP-1 posts ‘competitive’ ph. 2 results
background ▾
- •CX11 achieved 11.5% weight loss at 36 weeks in phase 2, meeting primary endpoints with acceptable tolerability (5% GI discontinuation rate, no severe adverse events or hepatic safety signals)
- •Results align with China phase 3 data and position CX11 competitively within oral GLP-1 space, though below Structure's reported 15.3% benchmark; multiple competitors (AZ's elecoglipron, Structure's aleniglipron) advancing simultaneously to phase 3
- •Corxel is initiating global pivotal phase 3 trials; watch for phase 3 readouts from Structure, AstraZeneca, and other oral GLP-1 entrants over next 12-24 months, and whether CX11 demonstrates sufficient differentiation versus injectables to capture market share
Corxel PharmaceuticalsVincentageAstraZenecaCX11elecoglipronaleniglipron
→ Read original articleClinical Trials•STAT News•Jun 24, 2026
Opinion: How I used public radio to recruit 20,000 participants for a peer-reviewed study on walking breaks
background ▾
- •Large real-world study of 20,000 participants confirms that brief walking breaks (5 minutes every 30 minutes) reduce blood glucose spikes by ~60% and provide cardiovascular benefits equivalent to medication plus structured exercise in sedentary individuals
- •Novel recruitment strategy leveraging public radio achieved unprecedented participant scale and geographic diversity, suggesting alternative models for clinical trial enrollment amid declining public trust in health institutions
NPRColumbia University Medical Center
→ Read original articleClinical Trials•Endpoints News•Jun 23, 2026
Pfizer late-stage ADC lung cancer fail calls cancer strategy into question
background ▾
- •Pfizer's late-stage ADC lung cancer trial failed, directly challenging a key pillar of the company's oncology portfolio strategy
- •ADC platform credibility at Pfizer is now in question, with potential ripple effects across other ADC programs in development
- •Investors and analysts will scrutinize whether Pfizer's broader cancer strategy requires fundamental repositioning or selective pruning of underperforming ADC programs
PfizerPfizer ADC lung cancer candidate (unnamed)
→ Read original article